Logo

Alopexx Partners with Bharat Biotech to Co-Develop and Commercialize AV0328 Anti-Microbial Vaccine

Share this
Alopexx

Alopexx Partners with Bharat Biotech to Co-Develop and Commercialize AV0328 Anti-Microbial Vaccine

Shots:

  • Alopexx and Bharat Biotech have partnered to co-develop & commercialize the former’s AV0328, a broad-spectrum anti-microbial vaccine, across India as well as other low income & lower middle-income countries
  • Bharat Biotech will pay one-time upfront, milestones as well as sales-based royalties linked to AV0328 in the licensed territories
  • AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), was effective against 15 distinct pathogens in preclinical study and well-tolerated in P-I study without any SAEs. It produced antibodies that effectively killed a variety of PNAG-expressing pathogens, showing promise as a broad-spectrum antimicrobial solution

Ref: Globenewswire | Image: Alopexx & Bharat Biotech

Related News: Bharat Biotech Reports Results of Covaxin (BBV152) in P-II/III Trial for the Treatment of COVID-19

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions